Key Developments: Integra LifeSciences Holdings Corp (IART.OQ)
38.61USD
1 Aug 2013
$-0.78 (-1.98%)
$39.39
$39.50
$39.50
$37.35
69,154
46,431
$44.37
$30.89
Latest Key Developments (Source: Significant Developments)
Integra LifeSciences Holdings Corp Reaffirms FY 2013 Guidance
Integra LifeSciences Holdings Corp announced that if continues to expect fiscal 2013 revenues of $840 million to $852 million. The Company is reaffirming its expectations for GAAP earnings per diluted share for fiscal 2013 to be between $0.90 and $1.20 and for adjusted earnings per diluted share to be between $2.40 and $2.70. According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $844 million and EPS of $2.52 for fiscal 2013. Full Article
Integra LifeSciences Holdings Corp Reaffirms FY 2013 Revenue Guidance-Conference Call
Integra LifeSciences Holdings Corp announced that for fiscal 2013, it expects revenue guidance of $840 million to $852 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $843 million for fiscal 2013. Full Article
Integra LifeSciences Holdings Corp Lowers FY 2013 Guidance
Integra LifeSciences Holdings Corp announced that for fiscal 2013, it expects revenues in the range of $840 million to $852 million. The Company is revising its expectations for GAAP earnings per diluted share for the fiscal 2013 to between $0.92 and $1.22 and for adjusted earnings per diluted share to between $2.40 and $2.70. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $855 million and EPS of $2.72 for fiscal 2013. Full Article
Integra LifeSciences Holdings Corp Issues FY 2013 Guidance In Line With Analysts' Estimates
Integra LifeSciences Holdings Corp announced that for fiscal 2013, it expects revenues to be between $865 and $880 million. The Company expects its GAAP earnings per diluted share for fiscal 2013 to be between $1.68 and $1.87 and adjusted earnings per diluted share to be between $3.08 and $3.27. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $875 million and EPS of $3.23 for fiscal 2013. Full Article
Integra LifeSciences Holdings Corp Announces Three-Year Contract With Premier Healthcare Alliance
Integra LifeSciences Holdings Corp announced that it was awarded a three-year group purchasing agreement with the Premier healthcare alliance, one of the group purchasing organizations in the United States. The agreement includes Jarit surgical and laparoscopic instruments, Ruggles- Redmond neuro/spine instruments, Padgett reconstructive and plastic surgery instruments and sterilization containers. Full Article
Integra LifeSciences Holdings Corp Receives Warning Letter In Andover, England Manufacturing Facility
Integra LifeSciences Holdings Corp announced that on November 5, 2012 it received a warning letter from the United States Food and Drug Administration (FDA) related to quality systems issues at its manufacturing facility located in Andover, England. The letter resulted from an inspection held at that facility in June 2012. The warning letter does not restrict the Company's ability to manufacture or ship products or import them into the United States. It also does not require the recall of products. The Company has provided detailed responses to FDA as to its corrective actions on a monthly basis and, since the conclusion of the inspection, has undertaken significant efforts to remediate the observations. Full Article
Integra LifeSciences Holdings Corp Receives FDA Clearance For Expanded Indication For Spinal Device
Integra LifeSciences Holdings Corp announced that the Food and Drug Administration (FDA) has approved an expanded indication for use of the Integra Vu aPOD Prime Intervertebral Body Fusion Device (IBD) in anterior lumbar interbody fusion (ALIF) procedures. The new stand-alone indication includes four points of fixation, which is composed of two screws and a SpinPlate. The Integra Vu aPOD Prime IBD will be featured at the Congress of Neurological Surgeons (CNS) annual meeting, October 6 - 10, 2012, in Chicago, Illinois. Full Article
Integra LifeSciences Holdings Corp Reaffirms FY 2012 Revenue Guidance-Conference Call
Integra LifeSciences Holdings Corp announced that for fiscal 2012, it expects revenues to be between $828 million and $838 million overall. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $835 million for fiscal 2012. Full Article
Integra LifeSciences Holdings Corp Raises FY 2012 Revenue Guidance; Reiterates FY 2012 EPS Guidance
Integra LifeSciences Holdings Corp announced that it has increased its expectations for fiscal 2012 revenues to $828-$838 million, at current exchange rates. The Company revised its GAAP earnings per diluted share for fiscal 2012 between $1.34 and $1.43 and reiterated its guidance for adjusted earnings per diluted share (EPS) of between $2.97 and $3.06. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $830 million and EPS of $3.04 for fiscal 2012. Full Article
Integra LifeSciences Holdings Corp Reaffirms FY 2012 Revenue Guidance; Raises Low End Of Prior FY 2012 EPS Guidance To A Range In Line With Analysts' Estimates
Integra LifeSciences Holdings Corp reaffirmed fiscal 2012 revenue guidance to a range of $820 million and $835 million, at current exchange rates. The Company is guiding to GAAP earnings per diluted share for the fiscal 2012 between $1.55 and $1.64 and to adjusted earnings per diluted share (EPS) of between $2.97 and $3.06. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $826 million and EPS of $3.00 for fiscal 2012. Full Article

Earnings vs.
Estimates